67,356 Shares in Natera, Inc. $NTRA Acquired by Foresite Capital Management VI LLC

Posted by Stanley Muller on Jun 16th, 2026

Foresite Capital Management VI LLC acquired a new stake in Natera, Inc. (NASDAQ:NTRA – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 67,356 shares of the medical research company’s stock, valued at approximately $15,431,000. Natera comprises approximately 4.7% of Foresite Capital Management VI LLC’s investment portfolio, making the stock its 7th biggest position.

A number of other institutional investors have also recently made changes to their positions in NTRA. Palladiem LLC bought a new position in shares of Natera in the fourth quarter worth approximately $31,000. Horizon Investments LLC purchased a new stake in Natera during the 3rd quarter valued at $32,000. Bank of Jackson Hole Trust grew its holdings in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after acquiring an additional 83 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new position in shares of Natera in the fourth quarter valued at about $41,000. Finally, Greenline Wealth Management LLC bought a new position in shares of Natera during the fourth quarter valued at about $41,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Price Performance

NTRA stock opened at $216.97 on Tuesday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The company has a market cap of $31.07 billion, a P/E ratio of -133.11 and a beta of 1.56. The firm has a 50-day moving average of $206.67 and a 200 day moving average of $215.69.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Robert W. Baird set a $265.00 price target on Natera in a research report on Friday, May 8th. Wells Fargo & Company increased their price objective on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Evercore reiterated an “outperform” rating and issued a $270.00 price objective on shares of Natera in a research report on Friday, May 8th. Finally, Piper Sandler reissued an “overweight” rating and set a $249.00 target price on shares of Natera in a research note on Tuesday, May 12th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.53.

Check Out Our Latest Stock Report on Natera

Insider Activity

In other news, Director Roelof Botha sold 78,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $220.31, for a total value of $17,184,180.00. Following the completion of the transaction, the director owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. This represents a 6.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gail Boxer Marcus sold 11,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the completion of the transaction, the director owned 6,183 shares of the company’s stock, valued at approximately $1,343,009.43. The trade was a 64.02% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 159,378 shares of company stock worth $34,640,860. Company insiders own 5.05% of the company’s stock.

About Natera

(Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.